List of Dove Medical Press academic journals

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication

Retrieved on: 
Thursday, October 27, 2022
23andMe, Therapy, Securities Exchange Act of 1934, Security (finance), U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Genomic Health, Stroke, Growth, Terminology, Risk, Genotype, Cholesterol, Food, Lijun International Pharmaceutical (Holding) Co. Ltd., Sumathi Best Television Current Reporting Award, Annual report, List of Dove Medical Press academic journals, Patient, SAMS, Pharmacogenomics, SLCO1B1, GLOBE, PGT, Simvastatin, FDA, SAN, Securities Act of 1933, Drug Quality and Security Act, Genetics, Genome, Pharmaceutical industry

The 510(k) clearance modifies the labeling of the previously authorized 23andMe SLCO1B1 Drug Transport report, removing the need for confirmatory testing and allowing the company to provide interpretive drug information based on genetic factors for simvastatin.

Key Points: 
  • The 510(k) clearance modifies the labeling of the previously authorized 23andMe SLCO1B1 Drug Transport report, removing the need for confirmatory testing and allowing the company to provide interpretive drug information based on genetic factors for simvastatin.
  • Simvastatin is a medication in the statin family of drugs, commonly prescribed to lower cholesterol to help reduce the risk of heart attack and stroke.
  • In 2020, simvastatin was the second-most commonly prescribed statin, and the thirteenth-most commonly prescribed medication overall, in the U.S.* A variation of a particular gene, SLCO1B1, influences the bodys response to simvastatin.
  • 23andMe underwent rigorous analytical validation in order to meet FDA requirements to remove the need for confirmatory testing of the 23andMe pharmacogenetics report for SLCO1B1.

Cancer Gene Therapy Market to be Worth $8.70 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Monday, October 24, 2022
Transfer, Pressure, SAN, Revenue, European Medicines Agency, Therapy, Government, Prevalence, List of Dove Medical Press academic journals, CAGR, National Cancer Institute, Research, Immunotherapy, Cancer, Incidence, Acute lymphoblastic leukemia, FDA, USD, Central nervous system, Pharmaceutical industry, Agriculture, Fine chemical

SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ --The global cancer gene therapy market size is expected to reach USD 8.70 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ --The global cancer gene therapy market size is expected to reach USD 8.70 billion by 2030, according to a new report by Grand View Research, Inc.
  • Biopharmaceutical companies held the largest market share in 2021 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy.
  • Read 150-page full market research report for more Insights, " Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By Region, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs.

Virtual Reality Experience to Help Ease Pediatric Patient Anxiety Developed by Before Inc. and Saritasa

Retrieved on: 
Wednesday, October 5, 2022
Franko, Adoption, Reality–virtuality continuum, Fear, IOT, Technology, Therapy, Virtual reality, Public health, VP, Inc., Solution, Patient, Mental health, University, DRS, Before, University of California, Irvine Medical Center, DevOps, Environment, VR, Anxiety, University of Newcastle School of Medicine and Public Health, Database, List of Dove Medical Press academic journals, TechCrunch, Medicine, Toy, Medical device, Medicine

NEWPORT BEACH, Calif., Oct. 5, 2022 /PRNewswire/ -- Saritasa Technology Solutions, innovation partners delivering new products and solutions to clients, and Before, Inc., have released a new virtual reality (VR) software prototype to get children comfortable with medical procedures before surgery. The unique VR experience gives children and young teenagers a chance to familiarize themselves with medical tools in a safe environment ahead of their medical procedure to relieve preoperative anxiety.

Key Points: 
  • Before Inc. provides products and services to help acclimate and mentally prepare patients and their families for medical procedures.
  • The degree of anxiety before a medical procedure varies but Pediatric Health, Medicine and Therapeutics reports that several studies indicate that 50% to 75% of pediatric patients suffer from preoperative stress.
  • Before, Inc. is developing its first product with Saritasa, a virtual reality perioperative walkthrough for pediatric patients and their families to reduce preoperative anxiety.
  • Saritasa specializes in custom software development, mobile development, augmented reality and virtual reality development, IoT solutions, web, database development, and DevOps.

Philips showcases clinical data and solutions designed to deliver better cardiac care with greater efficiency at TCT 2022

Retrieved on: 
Friday, September 16, 2022
PVD, Safety, Journal, Efficiency, Beth Israel Deaconess Medical Center, Research, PHG, Patient, Physician, Technology, Cardiology, Control, Philips, Aortic valve, Electrophysiology, 2D, Revascularization, Instant, Pilot in command, American College, 3D, Assistant, Sale, Journal of Comparative Effectiveness Research, List of Dove Medical Press academic journals, Interventional cardiology, Treatment, PCI, Decision-making, Guideline, NYSE, MD, Association, EPIQ, Length of stay, Physiology, AEX, SAS, ISR, Moyamoya disease, ESC, Appropriate use criteria, Veni, vidi, vici, Workflow, Health, TAVR, Calendar, Journal of the American College of Cardiology, Solution, General manager, Telemetry, Harvard Medical School, JACC, MCOT, IVUS, TCT, Medical imaging, Medicine, Medical device, Silviculture, Medicine

In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.

Key Points: 
  • In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.
  • At Philips, we are fully focused on supporting physicians to improve the health and well-being of the patients they serve.
  • Visitors to TCT 2022 will have access to Philips latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions.
  • Visit the Philips Engagement Hub to experience innovative cardiac solutions and follow the #TCT2022 conversation on @PhilipsLiveFrom throughout the event.

Medsembly Launches Interactive Mentorship Platform to Nurture Nextgen Healthcare Professionals

Retrieved on: 
Thursday, September 15, 2022
IOS, NextGen Healthcare, Growth, Life, Mentorship, Partnership, Apple, List of Dove Medical Press academic journals, CEO, Technology, Student, Family, Media contacts database, Android, School, MAG, Medicine, Job satisfaction, Google Play, Health, Management, Techstars

ATLANTA, Sept. 15, 2022 /PRNewswire/ -- Medsembly, a mentorship-driven career resource tool that connects aspiring healthcare students directly to professionals in their prospective careers, today announced the launch of its interactive all-in-one platform available for both iOS and Android devices. In partnership with schools, Medsembly gives students access to resources and mentors for one-on-one advice, and mentors enjoy a wide range of perks and discounts while supporting the nextgen healthcare workers.

Key Points: 
  • ATLANTA, Sept. 15, 2022 /PRNewswire/ -- Medsembly , a mentorship-driven career resource tool that connects aspiring healthcare students directly to professionals in their prospective careers, today announced the launch of its interactive all-in-one platform available for both iOS and Android devices.
  • In partnership with schools, Medsembly gives students access to resources and mentors for one-on-one advice, and mentors enjoy a wide range of perks and discounts while supporting the nextgen healthcare workers.
  • While mentorship plays a vital role in healthcare, according to a Journal of Healthcare Leadership report , oftentimes health professionals assume their first leadership positions without proper training and no formal mentoring.
  • Medsembly is utilizing technology to help healthcare students connect with professionals and mentors as they transition into their careers.

Asia Pacific Cancer Gene Therapy Market Report 2022: Increase in Financing for R&D in Cancer Gene Therapy Activities, as Well as An Increase in the Occurrence of Cancer Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 29, 2022
Pharmaceutical, Genetics, Health, Oncology, Transfer, Immunotherapy, Horizontal gene transfer, Genome, Industry, Government, Risk, Conditional sentence, Cancer, Gene, Country, Biotechnology, List of Dove Medical Press academic journals, Growth, Prevalence, Pharmaceutical industry, Vaccine

An increase in financing for R&D in cancer gene therapy activities, as well as an increase in the occurrence of cancer, are two significant reasons driving the market's expansion.

Key Points: 
  • An increase in financing for R&D in cancer gene therapy activities, as well as an increase in the occurrence of cancer, are two significant reasons driving the market's expansion.
  • Furthermore, favorable government laws for therapy are expected to promote numerous prospects that is expected to boost Cancer Gene Therapy Market over the forecast period.
  • However, the high cost of gene therapy, as well as undesired immune reactions, are likely to restrain the growth of the cancer gene therapy market.
  • In addition, the advantages of cancer gene therapy over conventional cancer medicines, as well as an increase in government backing and biotechnology financing that stimulates cancer gene therapy R&D, all contribute to the growth of the market.

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

Retrieved on: 
Thursday, July 7, 2022
Diagnosis, Review, FDA, Akari, Autoimmunity, Death, Patient, Annual report, CEO, Royal Manchester Children's Hospital, NHS foundation trust, LTB4, GLOBE, Thrombotic microangiopathy, HSCT, COVID-19, Time-invariant system, Failure, U.S. Securities and Exchange Commission, End organ damage, Intellectual property, Phase, University of Manchester, Manchester University NHS Foundation Trust, Transplant, Inflammation, Hope, List of Dove Medical Press academic journals, EMA, Risk, Food, BP, Hospital, Clinical trial, Private Securities Litigation Reform Act, Degenerative disease, Leukotriene B4, Nasdaq, TMA, SEC, Drug development, News, Eye, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seasonal adjustment, Therapy, Pharmaceutical industry, C5

Three patients with severe (nephrotic range proteinuria and elevated soluble C5b-9) HSCT-TMA have been enrolled in the clinical trial.

Key Points: 
  • Three patients with severe (nephrotic range proteinuria and elevated soluble C5b-9) HSCT-TMA have been enrolled in the clinical trial.
  • One patient completed more than 60 days of nomacopan treatment and subsequently was discharged from the hospital.
  • Another patient died from multi-organ failureunrelated to nomacopan treatment.Dosing has begun in the third patient.
  • The six-year-old patient who was discharged wastreated at a clinical trial site in Manchester, England by investigator Rob Wynn, M.D.

The Worldwide Cancer Gene Therapy Industry is Expected to Reach $5 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022
Genetics, Health, Oncology, Transfer, CAGR, Prostate, Skin, Cancer, Industry, Horizontal gene transfer, COVID-19, Kidney, Attention, Gene, Liver, Brain, Health, Virus, Research, List of Dove Medical Press academic journals, Cell proliferation, DNA, Marketing, Lymphatic system, Immune system, Investment, Lung, RNA interference, Radiation, Immunotherapy, Death, Patient, Pancreas, Cell, Dove Medical Press, Breast, Neoplasm, Vaccine

The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.

Key Points: 
  • The Global Cancer Gene Therapy Market size is expected to reach $5 billion by 2028, rising at a market growth of 21.2% CAGR during the forecast period.
  • The pipeline for cancer gene therapy is quite strong, and various industry participants have recently concentrated their efforts on developing a number of successful cancer gene therapies and vectors.
  • Pre-marketing approval is required for the marketing of cancer gene therapy, and it is a lengthy process that is closely reviewed.
  • Cancer gene therapy is a strategy for treating cancer that involves inserting therapeutic DNA into the patient's gene.

ALL ABOUT VISION RELEASES COMPREHENSIVE INFORMATION HUB IN RESPONSE TO THE GROWING MYOPIA CRISIS

Retrieved on: 
Thursday, June 16, 2022
Severe cognitive impairment, AAV, WHO, Cataract, UC, Brien Holden Vision Institute, List of Dove Medical Press academic journals, Associate, Glaucoma, Multimedia, University of California, Berkeley, Prevalence, Life, Risk, Birth control, Online shopping, DALLAS, Myopia, Vision

DALLAS, June 16, 2022 /PRNewswire/ -- All About Vision (AAV), the world's leading online portal for vision and eye care information, has launched a myopia information hub. Myopia has rapidly increased in prevalence worldwide, with an estimated 50% of the global population diagnosed by 2050. The hub contains the most updated information on myopia with more than 100 pieces of content.

Key Points: 
  • DALLAS, June 16, 2022 /PRNewswire/ -- All About Vision (AAV), the world's leading online portal for vision and eye care information, has launched a myopia information hub .
  • The hub contains the most updated information on myopia with more than 100 pieces of content.
  • All About Vision worked with researchers from the International Myopia Institute , the WHO , the Brien Holden Vision Institute and others to incorporate the latest data to create accessible content for the myopia hub.
  • "With the growing prevalence of myopia, we are prepared to remain ahead of the curve to meet readers where they are in their search for information."

Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Urine, List of Dove Medical Press academic journals, Therapy, LinkedIn, Headache, Blood pressure, Upper respiratory tract infection, Hypertension, Nasal congestion, Vibegron, Diarrhea, NYSE, Overactive bladder, Digoxin, Adult, Urinary tract infection, Allergy, Urinary incontinence, Doctor of Philosophy, Kidney, Urination, Urinary retention, Woman, Incidence, Urinary urgency, Man, Medicine, Nausea, Nocturia, Breast milk, Science, MD, Safety, Review, Vitamin, Sore throat, Twitter, OAB, Sumitomo Dainippon Pharma, Heart rate, Common, Liver, AES, FDA, Patient, Dietary supplement, Pharmaceutical industry, Copper, Fine chemical, Urology, THE EMPOWUR TRIAL, THE 40-WEEK EMPOWUR EXTENSION

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management ( https://bit.ly/Vibegron ).

Key Points: 
  • Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management ( https://bit.ly/Vibegron ).
  • Titled, An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder, the paper reviews published data from studies conducted over the past three years.
  • The 40-week EMPOWUR extension study evaluated safety in patients receiving GEMTESA for 52 weeks.
  • In EMPOWUR, the most frequently occurring treatment-emergent AEs (TEAEs) with incidence greater for vibegron than placebo were headache and nasopharyngitis.